Black Diamond Therapeutics, Inc.
Develops precision oncology therapies targeting families of oncogenic mutations.
BDTX | US
Overview
Corporate Details
- ISIN(s):
- US09203E1055
- LEI:
- Country:
- United States of America
- Address:
- ONE MAIN STREET, 14TH FLOOR, 2142 CAMBRIDGE
- Sector:
- Manufacturing
Description
Black Diamond Therapeutics, Inc. is a clinical-stage precision oncology company developing MasterKey therapies. These therapies are designed to target families of oncogenic mutations in patients with genetically defined cancers. The company's approach aims to provide a single solution for multiple mutations, thereby expanding the addressable patient population. The therapies are engineered to overcome treatment resistance, minimize toxicities related to wild-type proteins, and be brain-penetrant to treat central nervous system diseases. Primary areas of focus include non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Black Diamond Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Black Diamond Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Black Diamond Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
